Tumor Clinical Trials in Toronto, Ontario
85 recruitingToronto, Ontario, Canada
Showing 1–20 of 85 trials
Recruiting
Phase 1Phase 2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 1
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Advanced Solid Tumor
Senhwa Biosciences, Inc.52 enrolled8 locationsNCT04890613
Recruiting
Phase 3
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Brain Tumor
InSightec30 enrolled10 locationsNCT05317858
Recruiting
Phase 1
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Non-small Cell Lung CancerThoracic Tumors
Amgen500 enrolled83 locationsNCT06333951
Recruiting
Phase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Urothelial CarcinomaBladder CancerAdvanced/Metastatic Solid Tumors+1 more
Pfizer310 enrolled28 locationsNCT07090499
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Solid Tumors
Incyte Corporation710 enrolled34 locationsNCT06179160
Recruiting
Phase 1
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid TumorSolid Tumor+4 more
Ankyra Therapeutics, Inc97 enrolled5 locationsNCT06171750
Recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Breast CancerLiver CancerEsophageal Cancer+35 more
UMC Utrecht8,000 enrolled18 locationsNCT04075305
Recruiting
Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled27 locationsNCT07094113
Recruiting
Phase 1Phase 2
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Advanced Solid TumorsAdvanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer+2 more
Auricula Biosciences Inc.110 enrolled4 locationsNCT07148128
Recruiting
Phase 1Phase 2
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Advanced Solid Tumors
Bristol-Myers Squibb360 enrolled6 locationsNCT06730750
Recruiting
Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Advanced Solid Tumors
Bristol-Myers Squibb213 enrolled11 locationsNCT06544655
Recruiting
Phase 1Phase 2
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Advanced Solid Tumors
LigaChem Biosciences, Inc.300 enrolled8 locationsNCT05941507
Recruiting
Phase 2
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
Breast CancerSarcomaLung Cancer+6 more
British Columbia Cancer Agency200 enrolled2 locationsNCT04273061
Recruiting
Phase 1Phase 2
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Solid Tumors
ORIC Pharmaceuticals350 enrolled42 locationsNCT05315700
Recruiting
Phase 1Phase 2
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Advanced Solid TumorsCarcinomaNeoplasms+9 more
Marengo Therapeutics, Inc.365 enrolled32 locationsNCT05592626
Recruiting
Phase 1Phase 2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Breast CancerMelanomaGastrointestinal Neuroendocrine Tumor
University Health Network, Toronto500 enrolled1 locationNCT05196087